PHPN Stock Chart & Stats
€2.94
-€0.08(-2.65%)
At close: 4:00 PM EDT
€2.94
-€0.08(-2.65%)
Day’s Range― - ―
52-Week Range€1.61 - €5.80
Previous CloseN/A
Volume0.00
Average Volume (3M)23.00
Market Cap
€169.60M
Enterprise Value€307.34
Total Cash (Recent Filing)€14.11M
Total Debt (Recent Filing)€135.72M
Price to Earnings (P/E)―
Beta-0.35
Next Earnings
Aug 17, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding65,856,895
10 Day Avg. Volume0
30 Day Avg. Volume23
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)-2.11
Price to Sales (P/S)0.00
P/FCF Ratio-11.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.51Price Target Upside223.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Clarity: FDA Phase 3 AlignmentSecuring FDA agreement on endpoints, blinded central review and a traditional full‑approval pathway materially reduces regulatory uncertainty. This durable clarity supports a single confirmatory Phase 3 design, improving partnerability, fundraising prospects and the likelihood a successful trial can form the basis for approval.
Balance Sheet Repair Via Debt ConversionEliminating roughly $105.8M of debt meaningfully reduces interest burden and leverage, improving liquidity and financial flexibility to advance belapectin. This structural repair lowers near-term solvency risk and makes it easier to secure strategic partners or additional non-dilutive financing for Phase 3.
Improving Cash Burn TrajectoryA sustained reduction in cash burn signals improved operational efficiency and extended runway versus prior years. While still negative, the trend reduces immediate financing pressure, makes future capital raises less dilutive per dollar raised, and supports executing a Phase 3 program with better predictability.
Bears Say
No Product Revenue; Persistent LossesAs a clinical-stage biotech with no commercial products, Galectin lacks recurring revenue and remains reliant on capital markets. Persistent multi-year operating losses consume cash and create execution risk; without successful trial outcomes or partnerships, funding needs will persist over the medium term.
Deeply Negative Equity And Historic LeverageA deeply negative equity position and historically high debt indicate constrained financial flexibility and heightened solvency risk. Even with recent conversions, the prior structural weakness implies potential future financing constraints, creditor sensitivity and limited ability to absorb shocks during lengthy clinical development.
Dependence On Financing; Concentrated Shareholder ControlThe company’s business model depends on ongoing financings and major shareholder support; concentration of control increases governance and strategic risk. Reliance on a single backstop can limit negotiating leverage with partners and raise dilution or governance uncertainty if additional capital is required during Phase 3.
Galectin Therapeutics News
PHPN FAQ
What was Galectin Therapeutics Inc’s price range in the past 12 months?
Galectin Therapeutics Inc lowest stock price was €1.61 and its highest was €5.80 in the past 12 months.
What is Galectin Therapeutics Inc’s market cap?
Galectin Therapeutics Inc’s market cap is €169.60M.
When is Galectin Therapeutics Inc’s upcoming earnings report date?
Galectin Therapeutics Inc’s upcoming earnings report date is Aug 17, 2026 which is in 7 days.
How were Galectin Therapeutics Inc’s earnings last quarter?
Galectin Therapeutics Inc released its earnings results on May 15, 2026. The company reported -€0.069 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Galectin Therapeutics Inc overvalued?
According to Wall Street analysts Galectin Therapeutics Inc’s price is currently Undervalued.
Does Galectin Therapeutics Inc pay dividends?
Galectin Therapeutics Inc does not currently pay dividends.
What is Galectin Therapeutics Inc’s EPS estimate?
Galectin Therapeutics Inc’s EPS estimate is -0.08.
How many shares outstanding does Galectin Therapeutics Inc have?
Galectin Therapeutics Inc has 65,856,895 shares outstanding.
What happened to Galectin Therapeutics Inc’s price movement after its last earnings report?
Galectin Therapeutics Inc reported an EPS of -€0.069 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.383%.
Which hedge fund is a major shareholder of Galectin Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:PHPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Galectin Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€9.51 (223.62% Upside)
€9.51 (223.62% Upside)
Blogger Sentiment
Bullish
DE:PHPN Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
65.40%
Trailing 12-Months
Company Description
Galectin Therapeutics Inc
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
PHPN Stock 12 Month Forecast
Average Price Target
€9.51
▲(223.62% Upside)
Technical Analysis
Omeros
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Jade Biosciences
―
Tenaya Therapeutics
―